|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM377553727 |
| 003 |
DE-627 |
| 005 |
20250509142407.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
240914s2024 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1080/07366205.2024.2397288
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n1384.xml
|
| 035 |
|
|
|a (DE-627)NLM377553727
|
| 035 |
|
|
|a (NLM)39268899
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Mukherjee, Sonia
|e verfasserin
|4 aut
|
| 245 |
1 |
2 |
|a A HABA dye-based colorimetric assay to detect unoccupied biotin binding sites in an avidin-containing fusion protein
|
| 264 |
|
1 |
|c 2024
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 23.04.2025
|
| 500 |
|
|
|a Date Revised 23.04.2025
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Avidin-biotin binding, the most robust non-covalent protein-ligand interaction occurring in nature, has wide-ranging applications in biotechnology. A frequent challenge in these applications is accurately determining the number of unoccupied biotin binding sites in avidin-containing fusion proteins. We delineate a novel assay protocol in miniaturized format to quantify available biotin binding sites based on the affinity of the anionic dye 4'-hydroxyazobenzene-2-carboxylic acid for biotin binding sites within avidin. We apply this assay as a quality control assay to evaluate the number of available biotin binding sites in different fusion protein production batches. This method offers a streamlined alternative to fluorescence-based assays commonly employed to assess biotin binding, is less time-consuming than other methods and is applicable to diverse fusion proteins
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a avidin
|
| 650 |
|
4 |
|a binding assay
|
| 650 |
|
4 |
|a binding site occupancy
|
| 650 |
|
4 |
|a biotin
|
| 650 |
|
4 |
|a fusion protein
|
| 650 |
|
4 |
|a self-assembling vaccine
|
| 650 |
|
7 |
|a Biotin
|2 NLM
|
| 650 |
|
7 |
|a 6SO6U10H04
|2 NLM
|
| 650 |
|
7 |
|a Avidin
|2 NLM
|
| 650 |
|
7 |
|a 1405-69-2
|2 NLM
|
| 650 |
|
7 |
|a Recombinant Fusion Proteins
|2 NLM
|
| 650 |
|
7 |
|a Coloring Agents
|2 NLM
|
| 650 |
|
7 |
|a Azo Compounds
|2 NLM
|
| 700 |
1 |
|
|a Leblanc, Pierre
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Poznansky, Mark C
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Sluder, Ann E
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t BioTechniques
|d 1991
|g 76(2024), 10 vom: 07. Okt., Seite 485-494
|w (DE-627)NLM012627046
|x 1940-9818
|7 nnas
|
| 773 |
1 |
8 |
|g volume:76
|g year:2024
|g number:10
|g day:07
|g month:10
|g pages:485-494
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1080/07366205.2024.2397288
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_21
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_39
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_50
|
| 912 |
|
|
|a GBV_ILN_60
|
| 912 |
|
|
|a GBV_ILN_62
|
| 912 |
|
|
|a GBV_ILN_65
|
| 912 |
|
|
|a GBV_ILN_70
|
| 912 |
|
|
|a GBV_ILN_99
|
| 912 |
|
|
|a GBV_ILN_121
|
| 912 |
|
|
|a GBV_ILN_130
|
| 912 |
|
|
|a GBV_ILN_227
|
| 912 |
|
|
|a GBV_ILN_350
|
| 912 |
|
|
|a GBV_ILN_618
|
| 912 |
|
|
|a GBV_ILN_640
|
| 912 |
|
|
|a GBV_ILN_754
|
| 912 |
|
|
|a GBV_ILN_2001
|
| 912 |
|
|
|a GBV_ILN_2002
|
| 912 |
|
|
|a GBV_ILN_2003
|
| 912 |
|
|
|a GBV_ILN_2005
|
| 912 |
|
|
|a GBV_ILN_2006
|
| 912 |
|
|
|a GBV_ILN_2007
|
| 912 |
|
|
|a GBV_ILN_2008
|
| 912 |
|
|
|a GBV_ILN_2009
|
| 912 |
|
|
|a GBV_ILN_2010
|
| 912 |
|
|
|a GBV_ILN_2012
|
| 912 |
|
|
|a GBV_ILN_2015
|
| 912 |
|
|
|a GBV_ILN_2018
|
| 912 |
|
|
|a GBV_ILN_2023
|
| 912 |
|
|
|a GBV_ILN_2035
|
| 912 |
|
|
|a GBV_ILN_2040
|
| 912 |
|
|
|a GBV_ILN_2060
|
| 912 |
|
|
|a GBV_ILN_2099
|
| 912 |
|
|
|a GBV_ILN_2105
|
| 912 |
|
|
|a GBV_ILN_2121
|
| 912 |
|
|
|a GBV_ILN_2470
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 76
|j 2024
|e 10
|b 07
|c 10
|h 485-494
|